Article in BioWorld: Adrenomed’s adrecizumab shows hints of efficacy in open-label COVID-19 study

28. August 2020

August 2020,
by Cormac Sheridan

Read the full article here.

Search for:

Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer

1. February 2023

Adrenomed to attend upcoming industry and investor conferences

13. October 2022

Adrenomed appoints David Germonpré as Chief Financial Officer

12. July 2022

Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer

23. June 2022

PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients

11. April 2022

Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO

15. March 2022

More News

Media Coverage

Article in MedNous: Adrenomed prepares global study in septic shock

20. March 2023

Article on LaBiotech: Watch: Adrenomed tackling huge issue of sepsis

19. December 2022

Article in GoingPublic’s Plattform Life Sciences: “A phenomenal breakthrough is taking shape”

4. July 2022

Article in Pink Sheet’s Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial

12. April 2022

Article in Handelsblatt: Kampf gegen Sepsis – Adrenomed könnte nächste deutsche Biotech-Erfolgsgeschichte werden

19. October 2021

Article in Nature Biopharma Dealmakers: The key to treating sepsis and septic shock: matching treatment to causal pathophysiology

28. July 2021

Recent Events

J.P. Morgan Healthcare Conference & Biotech Showcase 2023 – Meet us in San Francisco

9. January 2023

Adrenomed to attend upcoming industry and investor conferences

13. October 2022

March conference update: 41st ISICEM and BIO-Europe Spring 2022

7. March 2022

Participation in Virtual J.P. Morgan 40th Annual Healthcare Conference 2022, 10 – 13 January 2022

26. November 2021

Weimar Sepsis Update, September 8 – 10, 2021

23. August 2021

ISICEM, August 31 – September 3, 2021

23. August 2021

More Events

Article in BioWorld: Adrenomed’s adrecizumab shows hints of efficacy in open-label COVID-19 study

Recent News

Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer

Adrenomed to attend upcoming industry and investor conferences

Adrenomed appoints David Germonpré as Chief Financial Officer

Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer

PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients

Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO

Media Coverage

Article in MedNous: Adrenomed prepares global study in septic shock

Article on LaBiotech: Watch: Adrenomed tackling huge issue of sepsis

Article in GoingPublic’s Plattform Life Sciences: “A phenomenal breakthrough is taking shape”

Article in Pink Sheet’s Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial

Article in Handelsblatt: Kampf gegen Sepsis – Adrenomed könnte nächste deutsche Biotech-Erfolgsgeschichte werden

Article in Nature Biopharma Dealmakers: The key to treating sepsis and septic shock: matching treatment to causal pathophysiology

Recent Events

J.P. Morgan Healthcare Conference & Biotech Showcase 2023 – Meet us in San Francisco

Adrenomed to attend upcoming industry and investor conferences

March conference update: 41st ISICEM and BIO-Europe Spring 2022

Participation in Virtual J.P. Morgan 40th Annual Healthcare Conference 2022, 10 – 13 January 2022

Weimar Sepsis Update, September 8 – 10, 2021

ISICEM, August 31 – September 3, 2021

Archive